cognitive cybersecurity intelligence

News and Analysis

UCB : presents latest data from generalized myasthenia gravis portfolio at 2023 AANEM Annual Meeting and MGFA Scientific Session -November 01, 2023 at 02:03 am EDT

UCB, a global biopharmaceutical company, is presenting its research on generalized myasthenia gravis (gMG) at two annual meetings. It will present additional results from the MycarinG and RAISE studies on its drugs rozanolixizumab-noli and zilucoplan. Both drugs, recently approved by the US FDA and Japanese authorities, are under review by the European Medicines Agency for the treatment of adults with gMG. UCB is also assessing the drugs in pediatric patients with gMG.

Source: –

Subscribe to newsletter

Subscribe to HEAL Security Dispatch for the latest healthcare cybersecurity news and analysis.

More Posts

Flow Security Launches GenAI DLP

Flow Security, an Israel-based data security platform, has incorporated a GenAI DLP module to secure data for GenAI services and applications. The move seeks to